BrightPath Biotherapeutics Co., Ltd., a clinical stage biotechnology company focused on the development of cell therapies derived from invariant natural killer T (iNKT) cells, and Artisan Bio. Inc, a precision genome engineering and drug discovery company, announced they have signed a research and licensing agreement to accelerate BrightPath's next-generation iNKT cell therapies to clinic. "This collaboration with Artisan provides BrightPath with the potential to create highly engineered allogeneic iNKT cellular therapy programs for a range of indications, including solid tumors," said Kenichi Nagai, BrightPath CEO.